China's NMPA authorises Santen’s glaucoma treatment application

Research Shows Glaucoma Is the Leading Cause of Blindness Among African Americans

According to the Glaucoma Research Foundation, glaucoma remains a leading cause of blindness worldwide, responsible for 9% to 12% of cases. Despite advancements in treatment, many still lose their sight because the disease progresses silently until significant damage occurs. Alarmingly, among the most affected groups are African Americans, who develop glaucoma three to four times more frequently than those of European descent. The condition also…

Santen receives marketing authorization application approval from NMPA of China for tafluprost/timolol maleate (Tapcom) in patients with open-angle glaucoma

Tapcom is a preservative-free, fixed-combination eye drop of tafluprost 0.0015% and timolol 0.5% for lowering intraocular pressure.

China's NMPA authorises Santen’s glaucoma treatment application

China’s NMPA has granted approval for the marketing authorisation application of Santen Pharmaceutical's Tapcom.